Literature DB >> 15036631

Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease.

Christophe Jollivet1, Anne Aubert-Pouessel, Anne Clavreul, Marie-Claire Venier-Julienne, Claudia N Montero-Menei, Jean-Pierre Benoit, Philippe Menei.   

Abstract

Glial cell line-derived neurotrophic factor (GDNF) offers the possibility to stimulate axonal regeneration of mesencephalic dopaminergic neurons, which are affected in Parkinson's disease. Nevertheless, a safe and efficient GDNF delivery system that may be used in clinical trials is still lacking. In a previous study, we showed that GDNF-releasing microspheres can deliver the neurotrophic factor for 2 months, allowing in a partial rat model of Parkinson's disease a sprouting of the preserved dopaminergic fibers and functional improvement 8 weeks after the treatment. The present study confirms these previous observations and shows that the amphetamine-induced rotation score is still decreased 24 weeks after the end of GDNF delivery. Nevertheless, the improvement was not statistically significant at the latest time point due to the spontaneous reinnervation observed in the model used.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036631     DOI: 10.1016/j.neulet.2003.11.051

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

1.  Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.

Authors:  C Requejo; J A Ruiz-Ortega; H Bengoetxea; A Garcia-Blanco; E Herrán; A Aristieta; M Igartua; L Ugedo; J L Pedraz; R M Hernández; J V Lafuente
Journal:  Mol Neurobiol       Date:  2015-06-04       Impact factor: 5.590

2.  Controlled release of glial cell line-derived neurotrophic factor from poly(ε-caprolactone) microspheres.

Authors:  Andrew Agbay; Nima Khadem Mohtaram; Stephanie Michelle Willerth
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

Review 3.  Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles.

Authors:  Akhand Pratap Singh; Arpan Biswas; Aparna Shukla; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2019-08-30

4.  Polylactic-co-glycolic acid microspheres containing three neurotrophic factors promote sciatic nerve repair after injury.

Authors:  Qun Zhao; Zhi-Yue Li; Ze-Peng Zhang; Zhou-Yun Mo; Shi-Jie Chen; Si-Yu Xiang; Qing-Shan Zhang; Min Xue
Journal:  Neural Regen Res       Date:  2015-09       Impact factor: 5.135

5.  From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF).

Authors:  Claire Géral; Angelina Angelova; Sylviane Lesieur
Journal:  Pharmaceutics       Date:  2013-02-08       Impact factor: 6.321

Review 6.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson's disease.

Authors:  Xavier d'Anglemont de Tassigny; Alberto Pascual; José López-Barneo
Journal:  Front Neuroanat       Date:  2015-02-13       Impact factor: 3.856

Review 7.  Growth Factor Therapy for Parkinson's Disease: Alternative Delivery Systems.

Authors:  Sarah Jarrin; Abrar Hakami; Ben Newland; Eilís Dowd
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.